A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma.

Trial Profile

A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Muparfostat (Primary)
  • Indications Liver cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors Progen Pharmaceuticals Limited
  • Most Recent Events

    • 22 Jul 2008 Status changed from recruiting to discontinued as reported by Progen Pharmaceuticals.
    • 11 Mar 2008 The first patient has been randomised.
    • 21 Dec 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top